

CBE ID

1860

Title

Patients with metastatic colorectal cancer and RAS gene mutation spared treatment with anti-epidermal growth factor receptor monoclonal antibodies

Endorsement Status

Endorsed

Is Under Review

No

Next Maintenance Cycle

Fall 2026

Previous Endorsement Cycle

Fall 2019

Initial Endorsement

Mon, 10/22/2012 - 08:01

Steward

American Society of Clinical Oncology

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

Patients with metastatic colorectal cancer and RAS gene mutation spared treatment with anti-epidermal growth factor receptor monoclonal antibodies

1.7 Measure Type

Process

1.8 Level of Analysis

Clinician: Group/Practice

1.14 Numerator

Anti-EGFR monoclonal antibody therapy not received

1.15 Denominator

Adult patients with metastatic colorectal cancer who have a RAS (KRAS or NRAS) gene mutation

1.20 Types of Data Sources

Paper Patient Medical Records

6.1.2 Current or Planned Use(s)

Payment Program, Public Reporting, Quality Improvement (Internal to the specific organization),
Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

6.1.3 Current Use(s)

Payment Program, Public Reporting, Quality Improvement (Internal to the specific organization),
Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

Exclusions

None

Measure Disclaimer

See copyright statement in Ad.6 above.

Planned Use

Public Reporting

Risk Adjustment

No risk adjustment or risk stratification

Target Population

Elderly

The measure developer is different from the measure steward

No

Steward Organization

American Society of Clinical Oncology

Steward POC email

Angela.Kennedy@asco.org